Videos

How to Choose the Appropriate Cardiovascular Information System

Patrick Campbell is the senior editor of Practical Cardiology, as well as its sister publication Endocrinology Network. Prior to joining these brands, he led coverage of cardiology and diabetes with HCPLive. Before joining parent company MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a freelance multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. In his free time, he enjoys traveling, sports, and exploring the great outdoors. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

In this edition of Inside Cardiology, a trio of advisory board members discuss a series of case reports, upcoming and newly released therapies for lipid disorders, and use of telehealth for the management of patients. 

Inside Cardiology: Lipid Management in 2021

Check out this interview with Louise McCullough, MD, PhD, Program Chair of ISC 21, where she offers perspective on mobile stroke units and what barriers prevent further implementation of the specialized ambulatory units.

Improving Patient Outcomes, Balancing Cost of Mobile Stroke Units with Louise McCullough, MD, PhD

Gregory Weiss, MD, offers perspective on the diagnosis and management of heart failure during 2020.

Gregory Weiss, MD: Heart Failure Management in 2020

Deepak Bhatt, MD, MPH, offers his perspective on how the ongoing pandemic has influenced clinical trials during 2020 and whether he thinks any changes will persist beyond the COVID-19 era. 

Year in Review: Clinical Trials in Cardiology During COVID-19

Practical Cardiology Advisory Board Member Brett Nowlan, MD, offers his perspective on the most important advances and topics in the field of lipidology from 2020.

Year in Review: Advances in Lipid Management During 2020

Learn more about the importance of educating patients on the differences between store-bought fish oil supplements and therapies derived from omega-3 such as icosapent ethyl (Vascepa).

The Importance of Educating Patients on Fish Oil Supplements vs Icosapent Ethyl

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

Muthiah Vaduganathan, MD: Key Takeaways from Sotagliflozin Data

Deepak Bhatt, MD, MPH, offers his thoughts on the most important REDUCE-IT analyses released in 2020 and why he disagrees with the notion results of the STRENGTH trial somehow impact the use of icosapent ethyl in clinical settings.

Deepak Bhatt, MD: STRENGTH, REDUCE-IT, and DHA

Deepak Bhatt, MD, MPH, offers his thoughts on the results of SCORED and SOLOIST as well as diving deeper into the implications of the data for sotagliflozin and SGLT2 inhibitors moving forward. 

Expert Interviews